Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
Supernus Pharmaceuticals (SUPN) has announced it will release its fourth quarter and full year 2024 financial results after market close on Tuesday, February 25, 2025. The company will host a conference call and webcast at 4:30 p.m. ET on the same day, featuring CEO Jack Khattar and CFO Tim Dec, who will present the results and host a Q&A session.
Investors can access the live webcast through the Events & Presentations section of Supernus's Investor Relations website. Pre-registration is available for participants who wish to join via phone. A replay of the call will be available on the company's website for 60 days following the live presentation.
Supernus Pharmaceuticals (SUPN) ha annunciato che pubblicherà i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 dopo la chiusura del mercato martedì 25 febbraio 2025. L'azienda ospiterà una conferenza telefonica e un webcast alle 16:30 ET lo stesso giorno, con la partecipazione del CEO Jack Khattar e del CFO Tim Dec, che presenteranno i risultati e condurranno una sessione di domande e risposte.
Gli investitori possono accedere al webcast in diretta attraverso la sezione Eventi e Presentazioni del sito web delle Relazioni con gli Investitori di Supernus. È disponibile la pre-registrazione per i partecipanti che desiderano unirsi via telefono. Una registrazione della chiamata sarà disponibile sul sito web dell'azienda per 60 giorni dopo la presentazione dal vivo.
Supernus Pharmaceuticals (SUPN) ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 después del cierre del mercado el martes 25 de febrero de 2025. La compañía llevará a cabo una conferencia telefónica y un webcast a las 4:30 p.m. ET el mismo día, con la participación del CEO Jack Khattar y del CFO Tim Dec, quienes presentarán los resultados y dirigirán una sesión de preguntas y respuestas.
Los inversores pueden acceder al webcast en vivo a través de la sección de Eventos y Presentaciones en el sitio web de Relaciones con Inversores de Supernus. La preinscripción está disponible para los participantes que deseen unirse por teléfono. Se podrá acceder a una grabación de la llamada en el sitio web de la empresa durante 60 días después de la presentación en vivo.
슈퍼너스 제약(SUPN)은 2024년 4분기 및 전체 연도 재무 결과를 2025년 2월 25일 화요일 시장 종료 후 발표할 것이라고 밝혔습니다. 회사는 같은 날 오후 4시 30분(동부 표준시)에 CEO 잭 카타르(Jack Khattar)와 CFO 팀 덱(Tim Dec)이 결과를 발표하고 질문 및 답변 세션을 진행하는 컨퍼런스 콜과 웹캐스트를 개최할 예정입니다.
투자자들은 슈퍼너스의 투자자 관계 웹사이트의 이벤트 및 프레젠테이션 섹션을 통해 실시간 웹캐스트에 접근할 수 있습니다. 전화로 참여하고자 하는 참가자들을 위해 사전 등록이 가능합니다. 실시간 발표 후 60일 동안 회사 웹사이트에서 통화 녹음에 접근할 수 있습니다.
Supernus Pharmaceuticals (SUPN) a annoncé qu'il publiera ses résultats financiers du quatrième trimestre et de l'année entière 2024 après la fermeture du marché le mardi 25 février 2025. L'entreprise organisera une conférence téléphonique et un webcast à 16h30 ET le même jour, avec la participation du PDG Jack Khattar et du CFO Tim Dec, qui présenteront les résultats et animeront une session de questions-réponses.
Les investisseurs peuvent accéder au webcast en direct via la section Événements et Présentations du site Internet des Relations Investisseurs de Supernus. Une préinscription est disponible pour les participants qui souhaitent se joindre par téléphone. Un enregistrement de l'appel sera disponible sur le site de l'entreprise pendant 60 jours après la présentation en direct.
Supernus Pharmaceuticals (SUPN) hat bekanntgegeben, dass die Finanzzahlen des vierten Quartals und des gesamten Jahres 2024 nach Marktschluss am Dienstag, den 25. Februar 2025, veröffentlicht werden. Das Unternehmen wird am selben Tag um 16:30 Uhr (ET) eine Telefonkonferenz und einen Webcast veranstalten, bei dem CEO Jack Khattar und CFO Tim Dec die Ergebnisse präsentieren und eine Fragen-und-Antworten-Runde leiten werden.
Investoren können über den Bereich Veranstaltungen & Präsentationen auf der Investor Relations-Website von Supernus auf den Live-Webcast zugreifen. Eine Voranmeldung ist für Teilnehmer, die telefonisch teilnehmen möchten, möglich. Eine Aufzeichnung des Anrufs wird 60 Tage nach der Live-Präsentation auf der Website des Unternehmens verfügbar sein.
- None.
- None.
ROCKVILLE, Md., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the fourth quarter and full year of 2024 after the market closes on Tuesday, February 25, 2025.
Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the fourth quarter and full year 2024 financial and business results on Tuesday, February 25, 2025 at 4:30 p.m. ET. Following management’s prepared remarks and discussion of business results, the call will be open for questions.
A live webcast will be accessible in the Events & Presentations section of the Company’s Investor Relations website at https://www.supernus.com/Investors.
Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.
Following the live call, a replay will be available on the Company's Investor Relations website at www.supernus.com/Investors. The webcast will be available on the Company’s website for 60 days following the live call.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for epilepsy, depression, and other CNS disorders.
For more information, please visit www.supernus.com/.
CONTACTS:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
ICR Healthcare
(443) 213-0505
peter.vozzo@icrhealthcare.com
FAQ
When will Supernus Pharmaceuticals (SUPN) report Q4 and full year 2024 earnings?
What time is the SUPN Q4 2024 earnings conference call?
How can investors access SUPN's Q4 2024 earnings call?
How long will SUPN's Q4 2024 earnings call replay be available?
